Loading
One shot of HPV vaccine was 97.5% effective against the two most dangerous HPV types, making it realistic to vaccinate the whole world.
Vaccine efficacy 97.5% against persistent HPV16/18 infection at 18 months (NEJM Evidence 2022), sustained at 36 months. Together with the IARC India cohort and Costa Rica trial data, it underpinned the WHO 2022 recommendation for one- or two-dose schedules, adopted by more than 60 countries by 2025 and roughly doubling the number of girls a fixed vaccine supply can protect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
2,275 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Vaccine efficacy against persistent HPV16/18 infectionprimary | Single dose nonavalent HPV | - | 97.5% | - | - | link |
Shares Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries, Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), Nonavalent HPV vaccine.
Shares Nonavalent HPV vaccine, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, HPV & HBV vaccination.
Shares Ian Frazer, Nonavalent HPV vaccine, HPV & HBV vaccination, Prevention we already have is not deployed.
Shares Ian Frazer, Nonavalent HPV vaccine, HPV & HBV vaccination, Cervical cancer.
Shares Ian Frazer, HPV & HBV vaccination, Cervical cancer, Head and neck squamous cell carcinoma.
Shares Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), HPV & HBV vaccination, Cervical cancer.
Shares Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer.
Shares Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer.